Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Diagnostics and treatment of genetic diseases using novel Cas enzymes
Company stage: Commercial (diagnostics), pre-clinical (therapeutics)
Diseases: COVID-19 (diagnostic), otherwise undisclosed
Genome editing tool: Cas14 and CasΦ
Funding stage: Private
Location: Brisbane CA, USA
Partners: Vertex Pharmaceuticals, Merck, GlaxoSmithKline
Mammoth Biosciences is focused on discovering novel CRISPR systems for diagnostics and therapeutic applications. The company is currently developing CRISPR-Cas12, Cas13, Cas14 and CasΦ, which may provide advantages over currently used systems. The DETECTRTM platform is based on these CRISPR systems, and has so far been applied out for SARS-CoV-2 testing. Although the lead programmes remain undisclosed, the company also develops its CRISPR systems for the treatment of genetic diseases. The company is co-founded by Nobel Laureate, Jennifer Doudna.